Skip to main content

Table 3 Summary of data analysis of changes in MMSE and five neuropsychometric tests reflecting parieto-occipital function

From: A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study

  Change from baseline of first treatment period to baseline visit of second treatment period (test of carry-over from baseline values) First treatment period: change from baseline visit to week 6 visit First treatment period: change from baseline visit to week 12 visit
  Donepezil (n = 8), mean (SD) Placebo (n = 10), mean (SD) Difference (95% CI) Donepezil (n = 8), mean (SD) Placebo (n = 10), mean (SD) Difference (95% CI) Donepezil (n = 8), mean (SD) Placebo (n = 10), mean (SD) Difference (95% CI)
MMSE 2.5 (1.4) −0.2 (1.7) 2.7 (1.3, 4.0) 1.0 (3.1) −1.5 (2.4) 2.5 (0.1, 5.0) 1.5 (2.7) −0.5 (2.4) 2.0 (−0.1, 4.5)
Simple calculation −0.9 (0.7)a 0.6 (1.1)b −1.5 (−2.6, –0.8)c −0.1 (0.7)a − 0.1 (0.8)b –0.0 (−0.7, 0.8)c 0.0 (1.3)a 0.4 (1.1)b −0.4 (−1.4, 0.8)c
     Donepezil vs placebo 6-week comparison Donepezil vs placebo 12-week comparison
     Donepezil first (n = 8), mean (SD) Placebo first (n = 10), mean (SD) Combined (n = 18), mean (95% CI) Donepezil first (n = 8), mean (SD) Placebo first (n = 10), mean (SD) Combined (n = 18), mean (95% CI)
Number location −1.0 (2.2) −0.9 (1.3) −0.1 (−1.7, 1.5) 0.8 (1.8) 0.2 (1.5) 0.5 (− 0.1, 1.5) 0.0 (2.4)a 0.7 (2.4) 0.4 (−0.8, 1.4)a
Letter cancellation −0 (25)a 2 (21) −2 (−22, 19)a −7 (39) −3 (15) −5 (−19, 8) −14 (35)a −1 (14) −8 (−23, 4)a
Dot counting −0.3 (1.5)a −1.0 (2.4)a 0.7 (−1.4, 2.3)b 1.3 (1.8) −0.2 (1.3)a 0.5 (−0.2, 1.2)a 1.3 (0.8)a −0.1 (1.7) 0.6 (−0.1, 1.1)a
Digit span 0.3 (1.5)b 0.0 (1.3)b 0.3 (−0.9, 2.0)d 0.6 (1.9) 0.1 (1.6) 0.4 (−0.4, 1.2) 0.0 (1.0)a −1 (0.8) −0.5 (−0.9, −0.1)a
  1. CI confidence interval, MMSE Mini-Mental State Examination, SD standard deviation
  2. aOne missing value
  3. bTwo missing values
  4. cThree missing values
  5. dFour missing values